DK stock · Healthcare sector · Biotechnology
N
Novo Nordisk A/S
NVO
NYSE157.14
USD
-0.84
(-0.53%)
Market Closed
40.74P/E
28Forward P/E
1.93P/E to S&P500
352.482BMarket CAP
- -Div Yield
Upcoming Earnings
- -
Shares Short
5/15/23
1.56M
Short % of Float
- -
Short % of Shares Outs.
0.07%
% Held by Insiders
0.01%
% Held by Institutions
8.61%
Beta
0.31
PEG Ratio
77.77
52w. high/low
172.97/95.02
Avg. Daily Volume
1.45M
Return %
Stock
S&P 500
1 year
36.99
(9.05)
3 years
154.97
50.26
5 years
179.29
38.50
Scale: |
High
Low
14.75
8.38
14.00
8.27
22.75
12.82
26.58
18.92
34.05
22.83
38.89
29.90
49.10
36.61
60.34
41.72
58.16
30.89
54.12
32.83
58.37
41.23
58.63
46.10
73.92
49.24
117.35
66.59
135.86
91.51
145.94
130.10
Currency:
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
13.28
14.78
17.05
20.94
23.47
28.46
31.19
33.87
41.98
44.18
45.16
46.22
51.39
54.39
60.33
78.12
Earnings per share
2.71
3.13
3.59
4.96
6.05
7.82
9.40
10.10
13.56
14.99
15.42
15.96
16.41
18.05
20.46
24.51
FCF per share
2.40
3.51
4.11
5.44
6.38
6.78
8.32
10.43
12.40
15.83
13.15
13.31
14.97
12.80
20.40
28.31
Dividends per share
0.71
0.91
- -
1.52
2.02
2.82
3.63
4.53
5.02
9.42
7.62
7.87
8.17
8.62
9.22
11.17
CAPEX per share
0.77
0.66
1.02
1.34
1.18
1.32
1.36
1.65
2.49
3.27
3.50
5.13
4.73
9.46
3.16
6.51
Book Value per sh.
10.21
10.70
11.93
12.73
13.25
14.82
15.89
15.37
18.27
17.89
20.14
21.42
24.26
27.13
30.31
36.85
Comm.Shares outs.
3,155
3,089
2,996
2,903
2,827
2,742
2,679
2,622
2,571
2,530
2,473
2,420
2,374
2,334
2,334
2,265
Avg. annual P/E ratio
3.9
3.9
3.1
3.4
3.8
3.7
3.6
4.4
3.9
3.2
2.8
3.0
3.1
3.6
4.3
4.5
P/E to S&P500
0.2
0.2
0.0
0.2
0.2
0.3
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.2
Avg. annual div. yield
6.7%
7.5%
- -
8.9%
8.7%
9.6%
10.6%
10.2%
9.4%
19.4%
17.9%
16.3%
16.0%
13.3%
10.5%
10.2%
Revenue (m)
41,889
45,666
51,078
60,776
66,346
78,026
83,572
88,806
107,927
111,780
111,696
111,831
122,021
126,946
140,800
176,954
Operating margin
21.4%
27.2%
29.2%
31.1%
33.7%
37.8%
37.7%
38.8%
45.8%
43.3%
43.8%
42.2%
43.0%
42.6%
41.7%
42.3%
Depreciation (m)
3,012
2,450
2,551
2,467
- -
2,693
2,799
3,435
2,959
3,193
3,182
3,925
5,661
5,753
6,025
7,362
Net profit (m)
8,535
9,666
10,768
14,403
17,097
21,432
25,184
26,481
34,860
37,925
38,130
38,628
38,951
42,138
47,757
55,525
Income tax rate
22.3%
24.0%
23.0%
21.2%
22.0%
22.9%
22.6%
22.3%
19.8%
20.7%
21.7%
18.9%
19.8%
20.7%
19.2%
19.6%
Net profit margin
20.4%
21.2%
21.1%
23.7%
25.8%
27.5%
30.1%
29.8%
32.3%
33.9%
34.1%
34.5%
31.9%
33.2%
33.9%
31.4%
Working capital (m)
13,675
16,149
19,251
18,817
18,812
18,525
17,833
12,604
14,267
12,330
13,024
4,903
3,473
(4,464)
(13,921)
(12,746)
Long-term debt (m)
961
984
970
504
502
- -
- -
- -
- -
- -
- -
- -
3,009
2,897
12,961
24,318
Equity (m)
32,223
33,058
35,734
36,965
37,448
40,632
42,569
40,294
46,969
45,269
49,815
51,839
57,593
63,325
70,746
83,486
ROIC
23.0%
25.6%
28.4%
37.3%
40.6%
51.8%
54.7%
61.1%
68.6%
75.8%
69.1%
68.4%
58.7%
56.9%
50.5%
46.4%
Return on capital
23.0%
25.1%
27.9%
33.1%
35.4%
45.1%
46.3%
44.3%
47.4%
49.1%
47.6%
43.1%
38.8%
36.9%
30.5%
28.8%
Return on equity
26.5%
29.2%
30.1%
39.0%
45.7%
52.7%
59.2%
65.7%
74.2%
83.8%
76.5%
74.5%
67.6%
66.5%
67.5%
66.5%
Plowback ratio
73.9%
71.0%
100.0%
69.5%
66.7%
63.9%
61.4%
55.2%
63.0%
37.2%
50.6%
50.7%
50.2%
52.2%
54.9%
54.4%
Div.&Repurch./FCF
90.2%
66.7%
52.9%
83.8%
90.3%
105.6%
106.0%
97.0%
94.4%
97.1%
109.7%
107.5%
97.7%
123.8%
86.0%
77.0%
Forex (DKK/USD)
0.196
0.188
0.193
0.179
0.174
0.177
0.184
0.163
0.145
0.141
0.161
0.154
0.150
0.164
0.153
0.142
Capital Structure
31 Dec · 2022 | Q4
All numbers in millions
Total liabilities
$ 157,771
Total assets
$ 241,257
Long-term debt
$ 24,318
Cash and equiv.
$ 12,653
Goodwill
$ 5,092
Retained earnings
$ 80,587
Common stock
2,262
Enterprise Value
$ 364,147
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
12,757
17,485
23,574
Receivables
32,184
46,799
57,505
Inventory
18,536
19,621
24,388
Other
2,332
(347)
2,623
Current assets
65,809
85,595
108,194
Acc. Payable
5,717
8,870
15,587
Debt due
7,459
13,684
1,466
Other
57,097
76,962
103,887
Current liabilities
70,273
99,516
120,940
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
25.68%
12.43%
9.02%
Cash flow
34.69%
22.13%
14.84%
Earnings
16.27%
9.65%
9.56%
Dividends
17.60%
7.52%
13.98%
Book value
18.01%
12.69%
8.05%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
33,875
30,006
30,927
32,138
126,946
2021
33,804
33,041
35,622
38,333
140,800
2022
42,031
41,265
45,566
48,092
176,954
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
5.10
4.55
4.41
3.99
18.05
2021
5.41
5.19
5.19
4.67
20.46
2022
6.27
5.88
6.36
6.00
24.51
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
5.38
- -
3.24
- -
8.62
2021
5.78
- -
3.44
- -
9.22
2022
6.93
- -
4.24
- -
11.17
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Lars Fruergaard Jorgensen
Full-time employees:
52,696
City:
Bagsvaerd
Address:
Novo Allé 1
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Recent News
· 4 Dec, 2022 · The Wall Street Journal
· 21 Jun, 2022 · The Wall Street Journal